(Scale All Share, Construction & Materials)



	Value Indicators:	EUR	Share data:		Description:	
Buy EUR <b>52.00</b>	DCF:	52.25	Bloomberg: Reuters: ISIN:	H5E GR H5EG DE000A0EQ578	Service provider for construous owner-occupied homes and property	
EUR 32.00	Market Snapshot:	EUR m	Shareholders:		Risk Profile (WRe):	2019e
	Market cap:	166.8	Freefloat	60.2 %	Beta:	1.6
Div	No. of shares (m):	4.0	Karl-Heinz Maerzke	39.6 %	Price / Book:	1.5 x
Price EUR	41.70 <sub>EV:</sub>	346.3	G. Janssen CEO	0.1 %	Equity Ratio:	30 %
Upside 2	4.7 % Freefloat MC:	100.4	André Müller MoB	0.1 %	Net Fin. Debt / EBITDA:	6.0 x
	Ø Trad. Vol. (30d):	333.53 th			Net Debt / EBITDA:	6.0 x

### FY 2019 guidance fulfilled; Positive outlook for 2020

Stated Figures Q1/2020:				
in EUR m	2019	2019e	2018	yoy
Sales	263,3	286,9	253,3	4%
EBIT	22,8	26,3	21,8	5%
EBIT adjusted	23,5	27,3	22,9	3%
EBIT-margin (adjusted)	8,9%	9,5%	9,1%	
EBT	23,6	25,4	21,2	12%
Net income	16,1	17,3	14,5	11%
EPS	4,04	4,33	3,62	12%
Order intake	296,5	286.6	278,6	6%

#### Comment on Figures:

- HELMA's 2019 sales increased by 4% yoy to EUR 263m but fell short of our expectation of EUR 287m. Growth was driven by HELMA Eigenheimbau which rose +15% to EUR 121.7m. The sales contribution from HELMA Wohnungsbau improved slightly to EUR 124m compared with the previous year (2018: EUR 122.6m). Sales at HELMA Ferienimmobilien of EUR 39.8m were lower than in 2018 (43.9m), as expected, but close to the guidance of EUR 40m p.a.
- The shortfall to our expectations on sales level is explained by our significantly higher estimate for sales volume at HELMA Wohnungsbau (WRe: EUR 140m). At first glance, we assume that our estimates were too optimistic as regards the selling-start for several projects.
- Even though EBIT growth was in line with sales growth, overall margin development was significantly below our expectation due to the mentioned sales mix. Higher-margin business at HELMA Ferienimmobilien and HELMA Wohnungsbau contributed lower, or only a slightly improved, sales volume.
- There was good development of order intake in 2019 with growth of 6% to EUR 297m, which exceeded our estimate of EUR 287m. This was driven by a recovery of order intake at HELMA Ferienimmobilien in H2 which led to an FY-increase of 10% to EUR 43.4m which leaves room for margin improvement again in 2020.
- With EUR 23.6m, HELMA **fulfilled its EBT target** at the lower end of its guidance (EUR 23.5-26m) but fell short of our estimate due to differences in the sales mix. The adjusted EBIT margin stood at 8.9% compared with 9.1%.
- Outlook for 2020 remains positive. Management is expecting an EBIT increase of at least 10% to >EUR 26m and expects further improvements in the following years.
- Overall, results look solid as HELMA was able to fulfil its guidance and is anticipating further growth potential in the coming years based on a strong pipeline volume of EUR 1.5bn. 10% growth of net income, driven by a higher sales volume, should be achievable. We confirm our Buy recommendation and we will revise our numbers downwards slightly.




Trailing 12 months:	34.7 %
Company events:	
23.03.20	FY 2019
24.03.20	RS LON
03.07.20	AGM
18.08.20	Q2

-0.3 %

FY End: 31.12. in EUR m	CAGR (18-21e)	2015	2016	2017	2018	2019e	2020e	2021e
Sales	10.4 %	210.6	263.8	267.4	253.3	286.9	315.5	340.8
Change Sales yoy		23.5 %	25.3 %	1.4 %	-5.3 %	13.3 %	10.0 %	8.0 %
Gross margin adj.	1.9 %	24.3 %	21.7 %	21.3 %	24.5 %	26.7 %	26.2 %	25.9 %
EBITDA	15.6 %	19.5	23.5	22.5	23.8	28.3	31.5	36.8
EBIT	16.8 %	17.8	21.7	20.2	21.8	26.3	29.5	34.7
Margin		8.4 %	8.2 %	7.6 %	8.6 %	9.2 %	9.4 %	10.2 %
EBT		15.0	19.6	19.1	21.2	25.4	28.6	33.5
Net income	16.4 %	10.0	13.5	13.0	14.5	17.3	19.5	22.9
EPS	16.5 %	2.69	3.37	3.25	3.62	4.33	4.89	5.72
EPS adj.	16.5 %	2.69	3.37	3.25	3.62	4.33	4.89	5.72
DPS	7.2 %	0.75	1.10	1.40	1.30	1.40	1.50	1.60
Dividend Yield		2.0 %	2.1 %	3.2 %	3.5 %	3.4 %	3.6 %	3.8 %
FCFPS		-10.49	-4.63	-4.31	-0.25	-0.69	-0.90	-0.24
FCF / Market cap		-28.4 %	-8.8 %	-9.8 %	-0.7 %	-1.7 %	-2.2 %	-0.6 %
EV / Sales		1.1 x	1.3 x	1.2 x	1.2 x	1.2 x	1.1 x	1.0 x
EV / EBITDA		11.9 x	14.3 x	14.4 x	12.9 x	11.9 x	11.0 x	9.6 x
EV / EBIT		13.1 x	15.5 x	16.1 x	14.1 x	12.8 x	11.7 x	10.2 x
P/E		13.6 x	15.6 x	13.5 x	10.2 x	9.6 x	8.5 x	7.3 x
P / E adj.		13.6 x	15.6 x	13.5 x	10.2 x	9.6 x	8.5 x	7.3 x
FCF Potential Yield	I	5.7 %	4.8 %	4.6 %	5.1 %	5.6 %	6.1 %	7.0 %
Net Debt		98.6	124.3	149.2	159.3	168.8	179.5	187.9
ROCE (NOPAT)		8.2 %	8.0 %	6.2 %	6.0 %	6.7 %	6.9 %	7.5 %
Guidance:	2019e: EBT E	UR 23.5-26m	1;					

Year to date:






### **Company Background**

- Provider of construction services for brick-built homes that can be adapted to individual tastes.
- Focus on product development, sale, planning and building administration. Construction is outsourced to subcontractors.
- Via HELMA Wohnungsbau GmbH, HELMA in its role as a developer, acquires larger areas zoned for residential construction with up to 250 building sites. Regional focus is on cities like Berlin, Hamburg, Hanover or Munich.
- Since early 2011 the company has been developing and selling holiday properties at the North Sea and Baltic Sea coasts as well as attractive lakeside locations via the subsidiary HELMA Ferienimmobilien.

### **Competitive Quality**

- Individualisation without additional costs: HELMA's homes are mainly distinguished by the range of individual design options at no extra cost.
- High expertise in the future market of energy-efficient houses: HELMA offers a broad range of energy-efficient houses, e.g. the ecoSolar house and, since May 2011, the EnergieAutarke Haus (energy self-sufficient home).
- Efficient sales concept: HELMA's 42 show houses throughout Germany are used by ca. 80 freelance sales representatives as a point of sale.
- Business model expansion into apartment building completes product range
- Successful advancement of the development business in the holiday property area since 2011. Gradual expansion of the market positioning makes attractive growth possible.





DCF model														
	Detailed	d forecas	t period				7	Γransition	al period					Term. Value
Figures in EUR m	2019e	2020e	2021e	2022e	2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	
Sales	286.9	315.5	340.8	364.6	386.5	405.9	422.1	434.7	447.8	456.7	465.9	475.2	482.3	
Sales change	13.3 %	10.0 %	8.0 %	7.0 %	6.0 %	5.0 %	4.0 %	3.0 %	3.0 %	2.0 %	2.0 %	2.0 %	1.5 %	1.5 %
EBIT	26.3	29.5	34.7	36.1	37.5	38.6	40.1	41.3	40.3	41.1	41.9	42.8	43.4	
EBIT-margin	9.2 %	9.4 %	10.2 %	9.9 %	9.7 %	9.5 %	9.5 %	9.5 %	9.0 %	9.0 %	9.0 %	9.0 %	9.0 %	
Tax rate (EBT)	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	
NOPAT	18.0	20.2	23.7	24.7	25.7	26.4	27.5	28.3	27.6	28.2	28.7	29.3	29.7	
Depreciation	2.0	2.0	2.1	2.9	3.1	3.2	3.4	3.5	3.6	3.7	3.7	3.8	3.9	
in % of Sales	0.7 %	0.6 %	0.6 %	0.8 %	0.8 %	0.8 %	0.8 %	0.8 %	0.8 %	0.8 %	0.8 %	0.8 %	0.8 %	
Changes in provisions	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Change in Liquidity from														
- Working Capital	21.5	24.0	24.5	10.3	9.0	6.2	5.0	4.8	4.3	4.2	3.8	3.3	2.4	
- Capex	3.0	3.0	3.0	3.3	3.5	3.7	3.8	3.9	4.0	4.1	4.2	4.3	4.3	
Capex in % of Sales	1.0 %	1.0 %	0.9 %	0.9 %	0.9 %	0.9 %	0.9 %	0.9 %	0.9 %	0.9 %	0.9 %	0.9 %	0.9 %	
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	-4.5	-4.8	-1.7	14.1	16.3	19.8	22.0	23.1	22.8	23.5	24.5	25.5	26.9	24
PV of FCF	-4.7	-4.7	-1.5	12.2	13.3	15.1	15.8	15.5	14.5	13.9	13.7	13.4	13.3	239
share of PVs		-2.98 %						38.1	5 %					64.83 %

Model parameter				Valuation (m)			
Derivation of WACC:		Derivation of Beta:		Present values 2031e	130		
				Terminal Value	239		
Debt ratio	45.00 %	Financial Strength	1.50	Financial liabilities	176		
Cost of debt (after tax)	1.7 %	Liquidity (share)	1.50	Pension liabilities	0		
Market return	7.00 %	Cyclicality	2.00	Hybrid capital	0		
Risk free rate	1.50 %	Transparency	1.00	Minority interest	0		
		Others	2.00	Market val. of investments	0		
				Liquidity	16	No. of shares (m)	4.0
WACC	6.44 %	Beta	1.60	Equity Value	209	Value per share (EUR)	52.25

Sens	itivity Va	lue per Sh	are (EUR	)													
		Terminal (	Growth								Delta EBIT	ī-margin					
Beta	WACC	0.75 %	1.00 %	1.25 %	1.50 %	1.75 %	2.00 %	2.25 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.93	7.4 %	30.02	31.56	33.23	35.03	37.00	39.14	41.49	1.93	7.4 %	16.42	22.63	28.83	35.03	41.24	47.44	53.65
1.77	6.9 %	36.61	38.52	40.59	42.85	45.33	48.06	51.08	1.77	6.9 %	22.60	29.35	36.10	42.85	49.60	56.35	63.10
1.68	6.7 %	40.33	42.45	44.78	47.32	50.12	53.23	56.68	1.68	6.7 %	26.13	33.20	40.26	47.32	54.38	61.45	68.51
1.60	6.4 %	44.37	46.76	49.37	52.25	55.43	58.98	62.95	1.60	6.4 %	30.03	37.43	44.84	52.25	59.66	67.06	74.47
1.52	6.2 %	48.79	51.47	54.43	57.70	61.34	65.42	70.01	1.52	6.2 %	34.34	42.12	49.91	57.70	65.49	73.28	81.07
1.43	5.9 %	53.63	56.67	60.03	63.77	67.96	72.68	78.03	1.43	5.9 %	39.13	47.35	55.56	63.77	71.98	80.20	88.41
1.27	5.4 %	64.89	68.83	73.25	78.23	83.88	90.36	97.85	1.27	5.4 %	50.56	59.78	69.00	78.23	87.45	96.67	105.90

- Modest increase of working capital quote and investment quote in the transitional period
- Strong working capital growth (2019-2021e) should enable higher growth rates in the years 2022-2024




Valuation							
	2015	2016	2017	2018	2019e	2020e	20216
Price / Book	1.9 x	2.6 x	2.0 x	1.5 x	1.5 x	1.3 x	1.2 >
Book value per share ex intangibles	16.97	19.48	21.53	23.65	26.81	30.30	34.44
EV / Sales	1.1 x	1.3 x	1.2 x	1.2 x	1.2 x	1.1 x	1.0 >
EV / EBITDA	11.9 x	14.3 x	14.4 x	12.9 x	11.9 x	11.0 x	9.6 >
EV / EBIT	13.1 x	15.5 x	16.1 x	14.1 x	12.8 x	11.7 x	10.2 >
EV / EBIT adj.*	12.7 x	15.1 x	14.7 x	13.3 x	12.3 x	11.4 x	10.0 x
P / FCF	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a
P/E	13.6 x	15.6 x	13.5 x	10.2 x	9.6 x	8.5 x	7.3 >
P / E adj.*	13.6 x	15.6 x	13.5 x	10.2 x	9.6 x	8.5 x	7.3 >
Dividend Yield	2.0 %	2.1 %	3.2 %	3.5 %	3.4 %	3.6 %	3.8 %
FCF Potential Yield (on market EV)	5.7 %	4.8 %	4.6 %	5.1 %	5.6 %	6.1 %	7.0 %
*Adjustments made for: -							
Company Specific Items							
	2015	2016	2017	2018	2019e	2020e	2021e
Order intake	269.4	286.8	245.4	278.6	286.6	296.1	306.1
Total output	264.0	274.0	283.3	279.0	301.9	330.5	355.8
Material expenses	212.8	216.8	226.4	217.1	225.2	248.0	267.5
Gross margin adj.	24.3 %	21.7 %	21.3 %	24.5 %	26.7 %	26.2 %	25.9 %



Consolidated profit & loss							
In EUR m	2015	2016	2017	2018	2019e	2020e	20216
Sales	210.6	263.8	267.4	253.3	286.9	315.5	340.8
Change Sales yoy	23.5 %	25.3 %	1.4 %	-5.3 %	13.3 %	10.0 %	8.0 %
Increase / decrease in inventory	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a
Own work capitalised	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a
Total output	264.0	274.0	283.3	279.0	301.9	330.5	355.8
Material expenses	212.8	216.8	226.4	217.1	225.2	248.0	267.5
Gross profit	51.2	57.3	57.0	61.9	76.7	82.5	88.3
Gross profit margin	24.3 %	21.7 %	21.3 %	24.5 %	26.7 %	26.2 %	25.9 %
Personnel expenses	17.5	19.8	20.9	23.9	26.9	28.5	29.0
Other operating income	1.0	1.7	1.7	1.6	1.0	1.0	1.0
Other operating expenses	15.2	15.7	15.2	15.9	22.5	23.5	23.5
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	19.5	23.5	22.5	23.8	28.3	31.5	36.8
Margin	9.3 %	8.9 %	8.4 %	9.4 %	9.9 %	10.0 %	10.8 %
Depreciation of fixed assets	1.7	1.8	2.3	2.0	2.0	2.0	2.1
EBITA	17.8	21.7	20.2	21.8	26.3	29.5	34.7
Amortisation of intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	17.8	21.7	20.2	21.8	26.3	29.5	34.7
Margin	8.4 %	8.2 %	7.6 %	8.6 %	9.2 %	9.4 %	10.2 %
EBIT adj.	18.4	22.2	22.1	23.0	27.3	30.3	35.5
Interest income	0.0	0.0	0.0	0.1	0.0	0.0	0.0
Interest expenses	2.8	2.1	1.2	0.7	0.9	0.9	1.2
Other financial income (loss)	0.0	0.0	0.1	0.0	0.0	0.0	0.0
EBT	15.0	19.6	19.1	21.2	25.4	28.6	33.5
Margin	7.1 %	7.4 %	7.2 %	8.4 %	8.8 %	9.1 %	9.8 %
Total taxes	5.0	6.0	6.1	6.6	8.0	9.0	10.5
Net income from continuing operations	10.0	13.5	13.0	14.5	17.4	19.6	22.9
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	10.0	13.5	13.0	14.5	17.4	19.6	22.9
Minority interest	0.0	0.0	0.0	0.0	0.1	0.1	0.1
Net income	10.0	13.5	13.0	14.5	17.3	19.5	22.9
Margin	4.7 %	5.1 %	4.9 %	5.7 %	6.0 %	6.2 %	6.7 %
Number of shares, average	3.6	4.0	4.0	4.0	4.0	4.0	4.0
EPS	2.69	3.37	3.25	3.62	4.33	4.89	5.72
EPS adj.	2.69	3.37	3.25	3.62	4.33	4.89	5.72
*Adjustments made for:							

Guidance: 2019e: EBT EUR 23.5-26m;


Financial Ratios							
	2015	2016	2017	2018	2019e	2020e	2021e
Total Operating Costs / Sales	116.1 %	95.0 %	97.5 %	100.8 %	95.4 %	94.8 %	93.6 %
Operating Leverage	1.1 x	0.9 x	-4.9 x	-1.5 x	1.6 x	1.2 x	2.2 x
EBITDA / Interest expenses	6.9 x	11.1 x	19.1 x	34.7 x	31.4 x	35.0 x	30.6 x
Tax rate (EBT)	33.3 %	30.9 %	31.9 %	31.4 %	31.5 %	31.5 %	31.5 %
Dividend Payout Ratio	27.4 %	32.5 %	43.0 %	35.8 %	32.2 %	30.6 %	27.9 %
Sales per Employee	829,205	909,800	879,664	779,311	940,530	1,034,583	1,117,350





Consolidated balance sheet							
In EUR m	2015	2016	2017	2018	2019e	2020e	20216
Assets							
Goodwill and other intangible assets	1.9	2.2	2.6	3.0	3.4	3.8	4.2
thereof other intangible assets	0.5	0.8	1.2	1.6	2.0	2.4	2.8
thereof Goodwill	1.4	1.4	1.4	1.4	1.4	1.4	1.4
Property, plant and equipment	16.3	16.4	16.6	19.1	19.7	20.3	20.8
Financial assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other long-term assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fixed assets	18.5	18.6	19.2	22.2	23.2	24.2	25.1
Inventories	154.4	173.8	199.9	220.2	240.0	260.0	280.0
Accounts receivable	56.6	71.8	76.8	77.2	79.4	85.6	92.4
Liquid assets	12.5	11.3	16.7	16.3	18.9	20.9	20.7
Other short-term assets	3.0	2.7	5.1	5.5	5.5	5.5	5.5
Current assets	226.5	259.7	298.5	319.2	343.9	372.0	398.6
Total Assets	245.0	278.2	317.7	341.4	367.1	396.2	423.7
Liabilities and shareholders' equity							
Subscribed capital	4.0	4.0	4.0	4.0	4.0	4.0	4.0
Capital reserve	41.5	41.5	41.5	41.5	41.5	41.5	41.5
Retained earnings	11.5	14.7	20.2	30.9	43.0	57.0	73.8
Other equity components	12.8	19.9	23.0	21.2	22.1	22.5	22.6
Shareholders' equity	69.8	80.1	88.7	97.6	110.6	125.0	141.9
Minority interest	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Total equity	69.9	80.2	88.8	97.7	110.7	125.1	142.1
Provisions	32.3	24.9	17.0	25.5	26.1	27.2	28.7
thereof provisions for pensions and similar obligations	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial liabilities (total)	111.1	135.7	165.9	175.6	187.7	200.4	208.6
thereof short-term financial liabilities	50.7	32.4	32.2	33.0	29.7	31.2	32.8
Accounts payable	8.1	9.7	8.5	9.5	9.4	10.4	11.2
Other liabilities	23.7	27.8	37.3	33.1	33.1	33.1	33.1
Liabilities	175.1	198.0	228.8	243.7	256.3	271.1	281.6
Total liabilities and shareholders' equity	245.0	278.2	317.7	341.4	367.1	396.2	423.7

Financial Ratios							
	2015	2016	2017	2018	2019e	2020e	2021e
Efficiency of Capital Employment							
Operating Assets Turnover	1.0 x	1.0 x	0.9 x	0.8 x	0.9 x	0.9 x	0.9 x
Capital Employed Turnover	1.3 x	1.3 x	1.1 x	1.0 x	1.0 x	1.0 x	1.0 x
ROA	53.7 %	72.7 %	67.7 %	65.1 %	74.6 %	80.7 %	91.0 %
Return on Capital							
ROCE (NOPAT)	8.2 %	8.0 %	6.2 %	6.0 %	6.7 %	6.9 %	7.5 %
ROE	18.0 %	18.0 %	15.4 %	15.6 %	16.6 %	16.6 %	17.1 %
Adj. ROE	18.0 %	18.0 %	15.4 %	15.6 %	16.6 %	16.6 %	17.1 %
Balance sheet quality							
Net Debt	98.6	124.3	149.2	159.3	168.8	179.5	187.9
Net Financial Debt	98.6	124.3	149.2	159.3	168.8	179.5	187.9
Net Gearing	141.1 %	155.0 %	168.0 %	163.0 %	152.4 %	143.5 %	132.3 %
Net Fin. Debt / EBITDA	505.7 %	530.0 %	662.4 %	670.1 %	596.9 %	569.2 %	511.1 %
Book Value / Share	17.4	20.0	22.2	24.4	27.7	31.2	35.5
Book value per share ex intangibles	17.0	19.5	21.5	23.7	26.8	30.3	34.4




Source: Warburg Research Source: Warburg Research Source: Warburg Research



Consolidated cash flow statement							
In EUR m	2015	2016	2017	2018	2019e	2020e	2021
Net income	10.0	13.5	13.0	14.5	17.4	19.6	22.9
Depreciation of fixed assets	1.7	1.8	2.3	2.0	2.0	2.0	2.1
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase/decrease in long-term provisions	-0.5	0.1	0.1	0.1	0.0	0.0	0.0
Other non-cash income and expenses	1.1	5.5	2.5	-1.6	1.0	1.0	1.0
Cash Flow before NWC change	12.3	21.0	17.9	14.9	20.4	22.6	26.0
Increase / decrease in inventory	-58.3	-16.8	-23.3	-16.9	-19.8	-20.0	-20.0
Increase / decrease in accounts receivable	-21.4	-14.9	-7.0	-1.3	-2.2	-6.2	-6.8
Increase / decrease in accounts payable	1.3	2.2	7.0	-1.0	-0.1	1.0	0.8
Increase / decrease in other working capital positions	28.5	-7.6	-7.9	8.3	2.0	2.0	2.0
Increase / decrease in working capital (total)	-49.9	-37.0	-31.3	-10.9	-20.1	-23.2	-24.0
Net cash provided by operating activities [1]	-36.2	-16.1	-13.3	4.1	0.2	-0.6	2.0
Investments in intangible assets	0.0	-0.5	-0.6	-0.4	-0.4	-0.4	-0.4
Investments in property, plant and equipment	-1.7	-1.9	-3.2	-4.4	-2.6	-2.6	-2.6
Payments for acquisitions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial investments	0.0	-0.3	-0.1	-0.1	0.0	0.0	0.0
Income from asset disposals	0.1	0.3	0.5	0.5	0.5	0.5	0.5
Net cash provided by investing activities [2]	-1.9	-1.8	-3.3	-4.4	-2.5	-2.5	-2.5
Change in financial liabilities	24.8	24.7	30.3	9.7	12.1	12.6	8.3
Dividends paid	-2.5	-3.2	-4.4	-5.6	-5.2	-5.6	-6.0
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	21.2	0.0	0.0	0.0	0.0	0.0	0.0
Other	0.3	-4.7	-3.9	-4.1	-2.0	-2.0	-2.0
Net cash provided by financing activities [3]	43.7	16.8	22.0	0.1	4.9	5.0	0.3
Change in liquid funds [1]+[2]+[3]	5.6	-1.2	5.3	-0.3	2.6	1.9	-0.2
Effects of exchange-rate changes on cash	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash and cash equivalent at end of period	12.5	11.3	16.7	16.3	18.9	20.9	20.7

Financial Ratios							
	2015	2016	2017	2018	2019e	2020e	2021e
Cash Flow							
FCF	-38.2	-18.5	-17.2	-1.0	-2.8	-3.6	-1.0
Free Cash Flow / Sales	-18.0 %	-7.0 %	-6.4 %	-0.4 %	-1.0 %	-1.1 %	-0.3 %
Free Cash Flow Potential	13.1	16.0	15.0	15.7	18.9	21.1	24.8
Free Cash Flow / Net Profit	-381.1 %	-137.3 %	-132.5 %	-6.8 %	-15.9 %	-18.4 %	-4.3 %
Interest Received / Avg. Cash	0.0 %	0.0 %	0.0 %	0.3 %	0.0 %	0.0 %	0.0 %
Interest Paid / Avg. Debt	2.9 %	1.7 %	0.8 %	0.4 %	0.5 %	0.5 %	0.6 %
Management of Funds							
Investment ratio	0.8 %	0.9 %	1.4 %	1.9 %	1.0 %	1.0 %	0.9 %
Maint. Capex / Sales	0.7 %	0.5 %	0.5 %	0.6 %	0.5 %	0.4 %	0.4 %
Capex / Dep	98.7 %	136.0 %	168.8 %	240.5 %	150.0 %	150.0 %	142.9 %
Avg. Working Capital / Sales	77.7 %	83.2 %	94.2 %	109.8 %	104.2 %	102.2 %	102.2 %
Trade Debtors / Trade Creditors	701.7 %	740.2 %	898.5 %	812.2 %	844.7 %	823.1 %	825.0 %
Inventory Turnover	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Receivables collection period (days)	98	99	105	111	101	99	99
Payables payment period (days)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Cash conversion cycle (Days)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.





#### **LEGAL DISCLAIMER**

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. All rights reserved.

#### **COPYRIGHT NOTICE**

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

# DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <a href="http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation">http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation</a>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

#### **SOURCES**

All data and consensus estimates have been obtained from FactSet except where stated otherwise.



#### Additional information for clients in the United States

- 1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
- 2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934.
- 3. Any recipient of the Report should effect transactions in the securities discussed in the Report only through J.P.P. Euro-Securities, Inc., Delaware.
- 4. J.P.P. Euro-Securities, Inc. does not accept or receive any compensation of any kind for the dissemination of the research reports from Warburg.

# Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5**% of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- -3- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
HELMA Eigenheimbau	3, 5	http://www.mmwarburg.com/disclaimer/disclaimer_en/DE000A0EQ578.htm



#### INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
<u>"_"</u>	Rating suspended:	The available information currently does not permit an evaluation of the company.

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING				
Rating	Number of stocks	% of Universe		
Buy	117	57		
Hold	72	35		
Sell	10	5		
Rating suspended	5	2		
Total	204	100		

#### WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	34	81
Hold	6	14
Sell	0	0
Rating suspended	2	5
Total	42	100

#### PRICE AND RATING HISTORY HELMA EIGENHEIMBAU AS OF 04.03.2020



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



FOURTIES			
EQUITIES	. 40, 40, 0000, 0070		
Matthias Rode Head of Equities	+49 40 3282-2678 mrode@mmwarburg.com		
RESEARCH			
Michael Heider	+49 40 309537-280	Eggert Kuls	+49 40 309537-256
Head of Research Henner Rüschmeier	mheider@warburg-research.com +49 40 309537-270	Engineering  Andreas Pläsier	ekuls@warburg-research.com +49 40 309537-246
Head of Research	hrueschmeier@warburg-research.com	Banks, Financial Services	aplaesier@warburg-research.com
Jan Bauer Renewables	+49 40 309537-155 jbauer@warburg-research.com	Franz Schall Automobiles, Car Suppliers	+49 40 309537-230 fschall@warburg-research.com
Jonas Blum	+49 40 309537-240	Malte Schaumann	+49 40 309537-170
Telco, Construction	jblum@warburg-research.com	Technology	mschaumann@warburg-research.com
Christian Cohrs Industrials & Transportation	+49 40 309537-175 ccohrs@warburg-research.com	Patrick Schmidt Leisure, Internet	+49 40 309537-125 pschmidt@warburg-research.com
Felix Ellmann	+49 40 309537-120	Oliver Schwarz	+49 40 309537-250
Software, IT	fellmann@warburg-research.com	Chemicals, Agriculture	oschwarz@warburg-research.com
Jörg Philipp Frey Retail, Consumer Goods	+49 40 309537-258 jfrey@warburg-research.com	Simon Stippig Real Estate	+49 40 309537-265 sstippig@warburg-research.com
Marius Fuhrberg	+49 40 309537-185	Cansu Tatar	+49 40 309537-248
Financial Services  Mustafa Hidir	mfuhrberg@warburg-research.com +49 40 309537-230	Cap. Goods, Engineering  Marc-René Tonn	ctatar@warburg-research.com +49 40 309537-259
Automobiles, Car Suppliers	mhidir@warburg-research.com	Automobiles, Car Suppliers	mtonn@warburg-research.com
Ulrich Huwald	+49 40 309537-255	Robert-Jan van der Horst	+49 40 309537-290
Health Care, Pharma Philipp Kaiser	uhuwald@warburg-research.com +49 40 309537-260	Technology  Andreas Wolf	rvanderhorst@warburg-research.com +49 40 309537-140
Real Estate	pkaiser@warburg-research.com	Software, IT	awolf@warburg-research.com
Thilo Kleibauer Retail, Consumer Goods	+49 40 309537-257		
	tkleibauer@warburg-research.com		
INSTITUTIONAL EQU			
Marc Niemann Head of Equity Sales, Germany	+49 40 3282-2660 mniemann@mmwarburg.com	Tobias Hald United Kingdom	+49 40 3282-2695 thald@mmwarburg.com
Klaus Schilling	+49 40 3282-2664	Maximilian Martin	+49 69 5050-7413
Head of Equity Sales, Germany	kschilling@mmwarburg.com	Austria, Poland	mmartin@mmwarburg.com +49 69 5050-7414
Tim Beckmann United Kingdom	+49 40 3282-2665 tbeckmann@mmwarburg.com	Christopher Seedorf Switzerland	cseedorf@mmwarburg.com
Lyubka Bogdanova	+49 69 5050-7411		
Ireland, Poland, Australia  Jens Buchmüller	lbogdanova@mmwarburg.com +49 69 5050-7415		
Scandinavia, Austria	jbuchmueller@mmwarburg.com		
Alexander Eschweiler	+49 40 3282-2669	Sophie Hauer	+49 69 5050-7417
Germany, Luxembourg	aeschweiler@mmwarburg.com	Roadshow/Marketing	shauer@mmwarburg.com +49 40 3282-2694
Matthias Fritsch United Kingdom	+49 40 3282-2696 mfritsch@mmwarburg.com	Juliane Niemann Roadshow/Marketing	+49 40 3282-2694 jniemann@mmwarburg.com
SALES TRADING			, -
Oliver Merckel	+49 40 3282-2634	Marcel Magiera	+49 40 3282-2662
Head of Sales Trading	omerckel@mmwarburg.com	Sales Trading	mmagiera@mmwarburg.com
Elyaz Dust	+49 40 3282-2702	Bastian Quast	+49 40 3282-2701
Sales Trading Michael Ilgenstein	edust@mmwarburg.com +49 40 3282-2700	Sales Trading Jörg Treptow	bquast@mmwarburg.com +49 40 3282-2658
Sales Trading	milgenstein@mmwarburg.com	Sales Trading	jtreptow@mmwarburg.com
MACRO RESEARCH			
Carsten Klude	+49 40 3282-2572	Dr. Christian Jasperneite	+49 40 3282-2439
Macro Research	cklude@mmwarburg.com	Investment Strategy	cjasperneite@mmwarburg.com
Our research can be t		TI 5	
Warburg Research	research.mmwarburg.com/en/index.html	Thomson Reuters	www.thomsonreuters.com
Bloomberg FactSet	MMWA GO www.factset.com	Capital IQ	www.capitaliq.com
For access please conta Andrea Schaper	<b>аст:</b> +49 40 3282-2632	Kerstin Muthig	+49 40 3282-2703
Sales Assistance	aschaper@mmwarburg.com	Sales Assistance	kmuthig@mmwarburg.com
			-